JP2011157386A5 - - Google Patents

Download PDF

Info

Publication number
JP2011157386A5
JP2011157386A5 JP2011084716A JP2011084716A JP2011157386A5 JP 2011157386 A5 JP2011157386 A5 JP 2011157386A5 JP 2011084716 A JP2011084716 A JP 2011084716A JP 2011084716 A JP2011084716 A JP 2011084716A JP 2011157386 A5 JP2011157386 A5 JP 2011157386A5
Authority
JP
Japan
Prior art keywords
estradiol
water
particles
cholesterol
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011084716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011157386A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011157386A publication Critical patent/JP2011157386A/ja
Publication of JP2011157386A5 publication Critical patent/JP2011157386A5/ja
Pending legal-status Critical Current

Links

JP2011084716A 2003-06-13 2011-04-06 避妊及びホルモン補充療法用の調合製剤 Pending JP2011157386A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47793903P 2003-06-13 2003-06-13
US60/477,939 2003-06-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006516535A Division JP4956185B2 (ja) 2003-06-13 2004-06-10 避妊及びホルモン補充療法用の調合製剤

Publications (2)

Publication Number Publication Date
JP2011157386A JP2011157386A (ja) 2011-08-18
JP2011157386A5 true JP2011157386A5 (enExample) 2012-03-22

Family

ID=33551788

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006516535A Expired - Fee Related JP4956185B2 (ja) 2003-06-13 2004-06-10 避妊及びホルモン補充療法用の調合製剤
JP2011084716A Pending JP2011157386A (ja) 2003-06-13 2011-04-06 避妊及びホルモン補充療法用の調合製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006516535A Expired - Fee Related JP4956185B2 (ja) 2003-06-13 2004-06-10 避妊及びホルモン補充療法用の調合製剤

Country Status (23)

Country Link
US (2) US7589082B2 (enExample)
EP (3) EP1663161B1 (enExample)
JP (2) JP4956185B2 (enExample)
CN (2) CN100594907C (enExample)
AT (1) ATE454885T1 (enExample)
AU (1) AU2004246870B2 (enExample)
BR (1) BRPI0411335A (enExample)
CA (2) CA2528545C (enExample)
CY (1) CY1109967T1 (enExample)
DE (1) DE602004025156D1 (enExample)
DK (3) DK1820494T3 (enExample)
EA (3) EA026709B1 (enExample)
ES (3) ES2537551T3 (enExample)
HU (1) HUE025147T2 (enExample)
IL (2) IL172466A (enExample)
MX (1) MX2008014654A (enExample)
NO (1) NO341540B1 (enExample)
OA (1) OA13307A (enExample)
PL (3) PL1844765T3 (enExample)
PT (3) PT1820494E (enExample)
SI (3) SI1820494T1 (enExample)
TW (1) TWI336623B (enExample)
WO (1) WO2004110408A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008014654A (es) 2003-06-13 2009-03-09 John Claude Savoir Formulacion de liberacion lenta de estradiol-progesterona para anticoncepción y terapia de remplazo hormonal.
JP2011516606A (ja) * 2008-04-14 2011-05-26 ポジ ビジョナリー ソリューションズ エルエルピー 様々な治療指標に必要な血漿プロゲステロン濃度を得るための方法および医薬組成物
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
US20120245552A1 (en) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination Therapy
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
US20170281646A1 (en) * 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
ES2754370T3 (es) 2016-07-19 2020-04-17 Evonik Operations Gmbh Procedimiento para la alcoxicarbonilación de compuestos con insaturación etilénica con ligandos monofosfina
CN119792305A (zh) * 2018-11-29 2025-04-11 因斯格纳公司 作为不育剂的苯甲酸雌二醇
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP3954364A1 (en) 2020-08-14 2022-02-16 Chemo Research, S.L. New modified release oral contraceptive composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
GB1367608A (en) * 1973-03-09 1974-09-18 Biolog Concepts Inc Oral pharmaceutical dosage form
US4218255A (en) * 1976-08-30 1980-08-19 University Of Dayton Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method
US4180560A (en) * 1976-10-26 1979-12-25 Syntex Corporation Inert core implant pellet
JPS5799562A (en) 1980-12-12 1982-06-21 Nippon Shinyaku Co Ltd Preparation of microcrystal
US5023092A (en) * 1988-06-16 1991-06-11 Ici Americas Inc. Mannitol having gamma sorbitol polymorph
IT1230566B (it) 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
IE71203B1 (en) 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
DE4130173A1 (de) 1991-09-11 1993-03-18 Bayer Ag Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
SE9301171D0 (sv) * 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
FR2747042B1 (fr) 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
EP0888790A1 (en) 1997-07-04 1999-01-07 PowderJect Research Limited Drug particle delivery device
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
SK288222B6 (sk) * 2000-12-14 2014-09-04 Ortho-Mcneil Pharmaceutical, Inc. Steroidné hormonálne prípravky a spôsoby ich prípravy
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
MX2008014654A (es) 2003-06-13 2009-03-09 John Claude Savoir Formulacion de liberacion lenta de estradiol-progesterona para anticoncepción y terapia de remplazo hormonal.

Similar Documents

Publication Publication Date Title
JP2011157386A5 (enExample)
CN102827153B (zh) 阿齐沙坦的晶型及其制备方法
JP2012521377A5 (enExample)
JP2008533007A5 (enExample)
JP2013529665A5 (enExample)
RU2011108220A (ru) Кристаллические микрочастицы действующего вещества, способ их изготовления и их применение в лекарственных средствах
JP2007302683A5 (enExample)
RU2016142819A (ru) Твердая композиция, содержащая аморфный софосбувир
JP2018504445A5 (enExample)
JP2014524442A5 (enExample)
JP2008512426A5 (enExample)
JP2011506330A5 (enExample)
JP2013018787A5 (enExample)
JP2014097964A5 (enExample)
JP2016535065A5 (enExample)
JP2015523546A5 (enExample)
JP2013535505A5 (enExample)
JP2012004269A5 (enExample)
HRP20231201T1 (hr) Kristalni metiltionij klorid hidrati
FI3258919T4 (fi) Nasaalinen jauheformulaatio hypoglykemian hoitoon
JP2014125461A5 (enExample)
JP2010512333A5 (enExample)
JP2009179634A5 (enExample)
JP2013538849A5 (enExample)
JP2006519246A5 (ja) 高純度フォンダパリヌクスナトリウム組成物